University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
1969

Investigation of the Role of Dopamine in Maintenance of Arterial
Hypertension
Harold Llewellyn Crossley
University of Rhode Island

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Crossley, Harold Llewellyn, "Investigation of the Role of Dopamine in Maintenance of Arterial
Hypertension" (1969). Open Access Master's Theses. Paper 189.
https://digitalcommons.uri.edu/theses/189

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

INVESTIGATION OF THE ROLE OF DOPAMil'JE IN MAINTENANCE
OF ARTERIAL HYPERTENSION

BY
HAROLD LLEWELLYN CROSSLEY III

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN

PHARlVIACOLOGY

UNIVERSITY OF RHODE ISLAND

1969

MASTER OF SCIENCE THESIS
OF
HAROLD LLEWELLYN CROSSLEY III

Approved:
Thesis Committee:
Chairman

~~~~~~~~~~~-----~~~~~~~-

Dean of the Graduate School

~~~~~~~~~~~~-

UNIVERSITY OF RHODE ISLAND

1969

ACKNOWLEDGEMENTS
The author wishes to express his most sincere appreciation to his
major professor, Dr. David R. De Fanti, for his assistance and patient
understanding throughout the investigation.
The author wishes to express his gratitude to the United States
Public Health Service for its support of this investigation through USPHS
Research Grant HE 09292.
The author wishes to sincerely thank the members of the graduate
committee for their advice and encouragement.
The author would especially like to thank his parents for their
continued guidance and understanding throughout the course of study •

./

ABSTRACT
The relationship between urinary dopamine levels and arterial blood
pressure was studied in normal, unilaterally nephrectomized, and renal
hypertensive male albino rats.
Experimental hypertension was produced by a unilateral nephrectomy
followed by compression of the contralateral renal artery.

The two operations

were spaced three weeks apart to allow for recovery.
Nine weeks after-the-second operatton; mean systolic blood pressure of
the renal hypertensive control group increased to 170 mm Hg. Mean systolic
blood pressure of the diethyldithiocarbamate (DDC)-treated renal hypertensive
group decreased abruptly after two weeks of treatment and remained at 105 mm
Hg throughout the nine week period. Mean systolic blood pressures of the normal
and unilaterally nephrectomized group of animals remained between 100-12 5 mm
Hg throughout the study. However, in comparisons with control groups, the
systolic blood pressures of the DDC-treated unilaterally nephrectomized and
normal groups of animals were significantly lower after four or seven weeks
of treatment respectively.
Urinary dopamine was extracted by adsorption onto alumina, converted
to its trihydroxyindole fluorophore and measured spectrofluorimetrically.
In comparisons with control groups, urinary dopamine levels (µ.g/24 hr,

µg/kg/24 hr) did not differ significantly in either the normal or DDC-treated
renal hypertensive group of animals. Mean dopamine levels remained relatively
constant throughout the nine week period and varied from 15 to 27 µg/24 hr and
13 to 21 µg/24 hr in the normal and renal hypertensive group of animals
respectively. Mean dopamine levels varied from 35 to 45 µg/kg/24 hr and 23
to 26 µg/kg/24 hr in the normal and renal hypertensive groups respectively.
After seven weeks of treatment, the mean urinary dopamine levels
(µg/24 hr) of the DDC-treated unilaterally nephrectomized group of animals
were significantly higher than controls. Mean dopamine levels of the DDCtreated group increased fro m 11 µg/24 hr to 23 µg/24 hr after the seventh week

·-

of treatment.

The control group remained relatively constant (15 µg/24 hr)

within the same period.
Mean body weights of the DDC-treated animals were significantly
lower than controls after six, four, and two weeks of treatment in the normal,
unilaterally nephrectomized, and renal hypertensive groups respectively.
In all groups of drug-treated animals there was a correlation between

decreased body weight, decreased amount of functional kidney tissue, and
decreased arterial blood pressure. No correlation was found between
blood pressure and urinary dopamine levels.
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I. INTRODUCTION
In the treatment of disease, a knowledge of the physiological and

metabolic derangements of the disease must first be considered. Only then
can the treatment be effectively employed.
Within the last decade many attempts have been made to show a relationship between erroneous catecholamine metabolism and the hypertensive
disease state. Because of their prominent pressor effects on the cardiovascular
system, norepinephrine and epinephrine have been the focus of this attention.
However, their precursor, dopamine, also possesses pressor effects.

This

led to a study by DeFanti and DeFeo (1963) of the role of dopamine in the etiology
of experimental renal hypertension in male albino rats.

These investigators

reported evidence indicating a positive correlation between arterial blood
pressure and urinary dopamine concentration in renal hypertensive rats.
To further investigate the role of dopamine in experimental hypertension,
the present investigation was designed to inhibit the enzyme dopamine-j3-hydroxylase, the enzyme responsible for the conversion of dopamine to norepinephrine,
with diethyldithiocarbamate. Evaluation was based on the effect of this drug on
systolic blood pressure, weight gains, and urinary dopamine levels in renal
hypertensive, unilaterally nephrectomized, and normal male albino rats.

4

II. REVIEW OF THE LITERATURE
In recent years much attention has been focused on the role of catecholamines in the pathogenesis of arterial hypertension. Suspected aberrations of catecholamine metabolism have led investigators to study the role
of circulating catecholamines and their metabolites during hypertension.
Interference v.rith the metabolism of these pressor substances could lead to
an accumulation of one or more of these compounds and conceivably maintain a hypertensive state.
Figure 1 represents the main pathway, first proposed by Blaschko (1939),
in the formation of the catecholamines.

The last three compounds in this

sequence represent the pressor catecholamines.
Evidence in support of this pathway was reported by Gurin and Delluva
14
3
(1947) who observed that
c- and H-phenylalanine labeled in the side chain
and ring respectively was incorporated into adrenal epinephrine (E).

Later,

Langemann (1951) measured the enzyme Dopa decarboxylase in the adrenal
14
medulla in rats. Leeper and Udenfriend (l956) administered c-3, 4-di14
hydroxyphenylalanine (Dopa) to rats and measured
c-norepinephrine (NE)
in the adrenals. It wasn't until 19 57 that Goodall and Kirshner, using
isotope dilution techniques, demonstrated unequivocally th3_t Blaschko's pro14
14
posed pathway was correct. Incubation of
c-tyrosine or c-Dopa with
bovine adrenal slices resulted in the label appearing in dopamine (DA), followed
by NE and subsequently E. Nagatsu et al. (1964) confirmed the synthetic pathway with the isolation and characterization of tyrosine hydroxylase.
Udenfriend (1966) observed tyrosine hydroxylase to be the rate - limiting
step in NE synthesis, because the amount of enzyme was limiting. When
tyrosine, Dopa, or DA was incubated with tyrosine hydroxylase, saturation
could only be achieved with tyrosine.

The Vmax for Dopa decarboxylase or

dopamine-(3-hydroxylase (DBH) [3, 4-dihydroxyphenylethylamine, ascorbate:
oxygen, oxidoreductase, E. C. 1.14. 2.1] was reported as two or three orders
of mag1utude higher than that for tyrosine hydroxylase.
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Reports that DBH may be the rate-limiting step are conflicting
(Musacchio et al., 1964; Nikodijevic et al., 1963; Udenfriend et al., 1966).
With the introduction of more sensitive qualitative and quantitative
analyses, the identification of the physiological mechanisms of inactivation
of the catecholamines was confirmed. A short summary of the catabolism
of the catecholamines appears in Figure 2.
Evidence that monoamine oxidase {monoamine: oxygen, oxidoreductase,
E. C. 1. 4. 3. 4] (MAO) oxidizes DA at a more rapid rate than either NE or E
was presented by Blaschko (1952).

This preferential attack appears to be due

to the lack of the ,B-hydroxyl group on the catecholamine moiety.

This report

suggested that because of the tremendous affinity of MAO for DA, this catecholamine might be the primary physiological substrate for the enzyme.
Blaschko further speculated that MAO may serve a regulatory role by limiting
the amount of DA available for metabolism to NE and E.
Axelrod

~al.

(19 57) demonstrated a predominant in vitro 0-methylation

of the catecholamines E and NE.

However, after intraperitoneal injection of

DA in the rat only 3% of the administered dose was excreted as its 0-methylated
derivative, 3-methoxytyramine. Pretreatment of the animals with iproniazid,
an MAO inhibitor, resulted in a five-fold increase of excreted 3-methoxytyramine.

These findings suggested that, although E and NE were largely 0-

methylated, DA was metabolized predominantly by MAO.
This was further substantiated by Goldstein et al. (1959) who administered
14
3-hydroxy-1- c-tyramine to rats and reported 60% of the administered
radioactivity excreted as 3-methoxy-4-hydroxyphenylacetic acid and 2-3%
excreted as 3-methoxytyramine. After pretreatment with iproniazid 31% of
administered radioactivity was excreted as 3-methoxytyramine and 10% as
3-hydroxytyramine.
Additional support that MAO should be the first enzyme involved in the
catabolism of DA was provided by Carlsson and Waldeck (1964) who reported
that both the enzyme and DA are concentrated within sympathetic nerve endings.
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Reports relating catecholamine levels and arterial hypertension have
been sparse arrl equivocal. Von Euler (1956) reported no significant
difference in NE levels when hypertensive subjects were compared to normals.
Alternatively, a two-fold increase in NE and E and a five-fold increase in DA
was observed in hypertensive patients by Weil-Malherbe and Bone (1957).
These authors also observed a greater variation in daily DA excretion than
with either NE or E.
Peart (1966) observed that there is hardly any evidence of credit which
· associates increased circulating catecholamines with hypertension. This
suggests, therefore, that, if a relationship does exist, some change in synthesis,
degradation, storage, release, or sensitivity of the vasculature to NE and E
may exist. However, this author also suggests that sympathetic tone is
normal in hypertension.
Studies into the possiblity of an altered turnover rate of any of the catecholamines during the hypertensive disease have been sporadic (Gitlow et al. ,
1964; Sjoerdsma et al., 1961; Mendlowitz et al. , 1959).
Although DA has been sho\vn to possess vasoactive properties, this catecholamine has been largely ignored as a possible participant in hypertension.
Dependent on the route of administration, DA has been reported as a pressor
agent in the cat (Holtz et al., 1962), dog (Holmes and Fowler, 1962), man
(Horwitz et al., 1962) and in the rat (Holtz et al., 1962; Pogrund et al., 1961).
In most cases the pressor response was a result. of increased cardiac output

with little or no change in peripheral resistance observed.
Reports of the distribution of. DA in mammalian tissues have been conflicting.

Schumann (1959) reported a wide distribution of DA in various tissues

in the rat, whereas Wegmann (1963) could detect the presence of DA only in the
spleen and kidney of the dog.

DA could not be found in the plasma of humans, dogs,

or rabbits (Anton and Sayre, 1964; Carlsson, 1959).
Bing (1941) reported evidence for the production of a pressor substance,
presumably DA, from the decarboxylation of Dopa in extracts of guinea pig

10

kidneys under anerobic conditions. He observed a similar reaction in vivo in
cat's ischemic kidney perfused with blood containing Dopa.

This report

suggests that deamina:tion but not decarboxylation of amino ·acids is incomplete
in anoxic kidneys.

This possibility was verified by Giordano et al. (1959), who

observed increased kidney Dopa decarboxylase and decreased kidney MAO
after prolonged hypertension in rabbits with renal ischemia. These altered
enzyme levels could conceivably lead to an accumulation of DA, NE, and/or
E in ischemic tissue.
DeFanti and DeFeo (1963)

r~ported

evidence indicating a positive

correlation between arterial blood pressure and urinary DA concentration in
renal hypertensive rats.
These studies suggested that decreased MAO activity in the ischemic
kidney results in an excess of DA in the tissues. The established pressor
activity of DA in man and animal and the reported increase in urinary DA
in the hypertensive rat suggested a role for DA in hypertensive disease.
If, under these conditions of decreased MAO activity, the enzyme

responsible for the conversion of DA to NE were inhibited by the use of
drugs, the excess DA present might result in an increased arterial pressure.
DBH, the enzyme responsible for the conversion of DA to NE, has been
reported to be inhibited by two classes of drugs. Analogs of the natural
substrate DA, with the a-carbon atom substituted with either Nor 0, proved
to be very potent competitive inhibitors of the active site on the enzyme
(Creveling et al., 1962). Although effective in vitro, the compounds in vivo
were hydrolyzed at a slow rate resulting in false transmitters with little or
no DBH inhibiting activity.
DBH has been shown to require copper as a cofactor in a concentration
of 0.65 to 1. 0 µg per mg of enzyme (Friedman and Kaufman, 1965). Binding
of the copper by drugs could inactivate this enzyme.
Disulfiram and one of its reduced metapolites, diethyldithiocarbamate
(DDC), belong to this second class of DBH inhibitors and have -been reported

11

to inhibit this enzyme in vivo (Goldstein and Anagnoste et al., 1964; Goldstein
1964). Goldstein and Anagnoste ~al. (1964) have observed
5
a 100% inhibition of DBH with 10- M DDC in vitro. Musacchio et a.I. (1966)
3
3
reported that DDC prevented the conversion of DA-H , tyramine-H and other
and Lauber

~al.,

phenylethylamines to their ,B-hydroxylated analogs. Increased DA levels with
a simultaneous decrease in NE in rat and rabbit small intestine have been
demonstrated by Collins (1965).

Carlsson et al. (1966) could not verify this

change in ileum tissue but did observe a significant change in the adrenals
and brain stem of the rat.
The findings of DeFanti and DeFeo (1963), the reported pressor activity
of DA in man and animal, and the availability of a suitable DBH inhibitor suggest
the need for further study into the possible role of DA in renal hypertension.

ill.

A.

INVESTIGATION

Objectives
The possibility that 3-hydroxytyramine (dopamine) was implicated in

renal hypertension was suggested by DeFanti and DeFeo (1963). They reported
a positive correlation between the increased arterial blood pressure and urinary
dopamine concentration in renal hypertensive rats. The objectives of this
study were to determine if there was an increase in the urinary excretion of
dopamine in rats rendered hypertensive by renal ischemia and if the increased
arterial blood pressure was significantly dependent upon an increase in dopamine.
B.

Materials and Methods
1.

General Considerations and Daily Protocol

1
Adult male albino rats of the Sprague-Dawley strain weighing125-150 g
were divided into three groups: surgically intact, unilaterally nephrectomized,
and renal hypertensive. Each group was further divided into two sub-groups:
2
animals receiving sodium diethyldithiocarbamate (66. 5 mg/kg) and animals
receiving the vehicle, 0.1 M phosphate buffer (pH 7. 4) 1 ml/kg. All animals
were injected on alternate days and housed in a room lighted from 7:00 a. m. to
3
7:00 p. m. and maintained at 22 ± O. 5° C. Purina rat chow and water were
provided ad libitum. Student's "t" test (Snedecor, 1956) was used for all comparisons reported.
2.

Production of Experimental Hypertension

Experimental renal hypertension was induced by the method of Goldblatt
et al. (1934) as modified by Drury (1938).

The method consisted of a unilateral

nephrectomy followed by compression of the right renal artery. The two operations were spaced three weeks apart to allow for the recovery of the animals.
1.

Charles River Breeding Farms, North Wilmington, Massachusetts.

2.

J. T. Baker Chemical Company, Phillipsburg, New Jersey.

3.

Ralston Purina, St. Louis, Missouri.
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The unilateral nephrectomy was performed on the right kidney by making
a dorsolateral incision an inch in length parallel to the spinal cord. The
kidney was palpated and located retroperitoneally to the abdominal cavity and
laterally to the incision. The organ was forced through the incision and
exposed for ligation with nylon thread.

The artery, vein and ureter were

ligated; the organ was then excised and frozen in liquid nitrogen for later
analysis.

The adrenal gland remained intact. The incision through the muscle

was closed with 3-0 silk suture and the epidermal incision closed with stainless
steel wound clips.
Approximately three weeks after the first operation the left renal artery
was located by making a one inch ventrolateral incision in the lower abdominal
area.

The artery was separated from the renal vein, and a stylet approximately

one third the size of the artery was placed parallel to the vessel. A nylon suture
was looped around both stylet and vessel and secured. The stylet was withdrawn
allowing the artery to expand to one-third of its normal size. The incision was
closed in the manner previously mentioned. All animals were fasted for
twenty-four hours prior to both operations to facilitate operative procedures.
3.

Blood Pressure Measurement

The systolic blood pressure of all animals was monitored on a bi-weekly
basis using the tail cuff method (Coates, 1968). The method utilizes an inflatable tail cuff placed about one centimeter from the base of the tail and con1
nected to a Physiograph manometer system. The tail was passed through a
2
holder to brm'g it into contact with a Beckman microphone transducer which
2
was connected to an Infraton signal divider adjusted for maximum pulse. This
3
lead was then connected to an HP oscilloscope . As the cuff was inflated, circulation stopped, and no pulses were transferred to the oscilloscope.

Con-

versely, as the cuff was deflated, the circulation was restored, and, at the
point where pulses reappeared, the impulses were observed on the oscilloscope
1.

E & M Instruments, Houston, Texas.

2.

Beckm an Co., Palo Alto, Californi a .

3.

Model 130 B., He wlett-Packa r d Co.,

P ~l-10

Alto, California.
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and the pressure read on the manometer.

Each value was the mean of three

separate determinations spaced a minute apart.
4.

Weight Gain Measurement

The effects of treatment with drug and vehicle on the individual body
weights of the animals were determined. All animals were weighed to the
1
nearest gram at the time of injection on an Ohaus small animal balance . The
individual weights of the drug-treated animals were compared with the weights

of the

control group on a bi-weekly basis.
5.

Collection of Urine

The animals from each group were selectively paired in an effort to house
animals of similar weights. Urine samples passed through stainless steel
funnels were collected over O. 5 ml of concentrated sulfuric acid.

The acid

hydrolyzed any conjugated dopamine and maintained an acid pH to avoid auto-:oxidation to 6-0H dopamine.

The samples were stored in test tubes at

0

-4o c

for later analysis.
6.

Extraction of Urine

The urine samples were centrifuged for twenty minutes, and 10 ml of the
supernatant was decanted into a clean test tube.

Two ml of O. 2 M disodium

ethylenediamine tetraacetate was added to the sample with two drops of concentrated hydrochloric acid.
cooled.

The samples were boiled for twenty minutes and

The samples were then adjusted to pH 8. 4 with 1 N NaOH, and 1 ml

of an antioxidant (sodium metabisulfite 10 mg/ml) was added.

The samples were
2
passed through a column prepared by the addition of aluminum oxide suspended
in 10 ml of 0.1 M ammonium acetate buffer, pH 8, and 0. 28 ml 0.1 N NaOH.

The alumina used was a chromatographic quality.
diameter of 0. 6 cm and a length of 7. 5 cm.

The column had an inside

The flow rate was adjusted to

1.

Ohaus Scale Corporation, Union, New Jersey.

2.

British Drug Houses, LTD; exclusive United States Distributors GallardSchlesinger Manufacturing Corp. , Long Island, New York.
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2 ml/min. by a Hoffman clamp. Bertler et al. (1958) have demonstrated
+
that Dopa ·will readily pass through the Na form of the alumina. Since Dopa
has the same fluoresc'e nce characteristics as ~opamine, it was desirable to
pass a 5 ml portion of sodium acetate 0.1 M through the column, prior to elution
to eliminate any contaminating Dopa. The samples were eluted by two 5 ml
portions of 0. 2 N acetic acid.
7.

Development of Sample

Development procedure was carried out at room temperature according
to the method of Carlsson and Waldeck (1958) as modified by Coates (1968). A
3 ml aliquot of the eluate was adjusted to pH 6. 5 with the addition of 1 ml of O. 3M
potassium carbonate.

The samples were treated with 1 ml of 0.1 M phosphate

buffer pH 6. 5 and the volumes diluted to 7 ml with glass distilled water. Two
drops of a O. 25 M iodine solution were added to each sample.

Three minutes

after the addition of iodine, 1 ml of alkaline sulfite reagent (500 mg sodium
sulfite. 7 H 0 per ml water diluted to 10 ml with 5N NaOH) were added to the
2
samples. After four minutes, 1 ml of 6 N acetic acid was added to all samples.
The samples were diluted to 10 ml with glass distilled water, boiled for 10
minutes and the supernatant decanted to quartz cuvettes. The cuvettes were
1
irradiated at 253 mµ in ultraviolet light for ten minutes to sustain fluorescence.
The sample fluorescence was measured at 370 mµ on an Aminco-Bowman spectrophotofluorometer2. Activation wavelength was 325 mµ (uncorrected instrument
values). A tissue blank which contained a 3 ml eluate aliquot was prepared and
assayed as above, except that 4. 5 N NaOH was substituted for the alkaline sul-

fite reagent. Two drops of a sodium sulfite solution (500 mg/ml) were added
prior to centrifugation to remove the remaining iodine color to avoid quenching.
A standard curve of known dopamine concentration was obtained with each set
of samples. A linear relationship between fluorescence and dopamine concentration as reported by Carlsson and Waldeck (1958), DeFanti (1961), and
1.

Chromato-Vue, Black Light Eastern Corp., New York, New York.

2.

American Instrument Co ., Inc., Silver Springs , 1\lar yland. Slit Arrangement number 3. Fuse d qun.rtz cells were used .
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Coates (1968) was found to exist up to 0. 5 µg/ml of dopamine (Figure 3).
An estimate of the dopamine content was made by dividing the corrected
fluorescent intensities of the unknowns by a value calcuaited to represent the
fluorescent intensity of a solution of dopamine containing 0.1 µg/ml.

The

fluorescent intensity contributed by the reagents was subtracted from the
fluorescent intensity

o~

the standard solutions.

The corrected values were

adjusted and averaged to obtain a single value which represented the fluorescent
intensity of a 0.1 µg/ml solution of dopamine.

Coates (1968) summarizes the

mechanics as follows:
I

Where I

s

Fs

0.1 I
s =(F s -R.B.x-c ) n

=

fluorescent intensity of a 0.1 µg/ml solution of dopamine

=

uncorrected fluorescent intensity of the developed solutions at
concentration C

R. B. = fluorescent intensity of the reagent blank
C

= final concentrations of dopamine in µg/ml

n

= the number of determinations

and finally:
C = (F -B ) /I
u
u
u
s
=

the concentration of dopamine (µg/ml) in the developed solution
of the unknown

u

=

the uncorrected fluorescence intensity of the developed solution
of the unknown

Bu

=

the fluorescent intensity of corresponding blank of the unknown

I

=

the fluorescent intensity of the standard as determined above

Where C
u
F

s

Since the final volume of the developed solutions was 10 ml, the total
dopamine content of a 3 ml column aliquot was equivalent to l _O times the concen-
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Fig. 3. Fluorescence intensity at varying concentrations of dopamine.
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tration in µg/ml (10 C ) and the total in a 10 ml eluate to 100 C /3.

u

u

The total

amount of dopamine in a sample was then calculated by the use of the follO'wing
formula:

Where Dt

=

the total qua.µtity {µg) of dopamine in a sample

V
1

= the volume

V2

= the total volume (ml) of the sample

Cu

=

(ml) of the sample extracted for dopamine content

the concentration of dopamine {µg/ml) in the developed solution
of the unknown

This method of dopamine determination provided accurate recoveries.
The average recovery obtained for knovvn concentrations of dopamine from
+
0.2 N acetic acid was 88.2 - 6. 5%, (Table I).
Throughout the experimental period internal standards (known amounts
of dopamine added to the urine prior to processing) were determined at
selected intervals.

The mean recovery was 84. 3 : 8. 7% (Table II).
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Table I
Percent recovery of dopamine from O. 2 N acetic acid

Dopamine added (µg)

Dopamine fotind (µg)

% Recovery

2.00

1. 68

84. 0

2.00

1. 85

93.0

2.00

1. 80

90.0

2.00

1. 83

91. 3

2.00

1. 38

69.0

2.00

1. 85

92. 5

4.00

3. 56

89.0

4.00

3.74

93.5

4.00

3.90

97.5

4.00

3. 51

87.8

4.00

3.61

86.3

4.00

3.69

88.1

6.00

5.45

90.8

6.00

5. 71

95.1

6.00

5.49

91. 5

6.00

4.76

79.2

6.00

5. 47

87.1

6.00

4. 95

83. 0

Mean recovery + standard deviation

-

=

88.2 ~ 6. 5%

20

Table II
Percent recovery of dopamine added to urine samples

Total dopamine (µg)
Calculated
Found

%

Endogenous
dopamine (µg)

Added
dopamine (µg}

2.29

2.00

4.29

3. 65

88

1. 33

2.00

3.33

2.33

70

2.30

2.00

4.30

3.78

86

1. 90

2.00

3.90

2.97

76

2.50

2.00

4.50

4.20

93

0.93

2.00

2.93

2. 53

86

3.17

2.00

5.17

4.23

81

1. 86

2.00

3.86

3.90

101

1.43

3.00

4.43

3.60

81

1. 09

4.00

5.09

4.09

80

Mean recovery ~ standard deviation

=

84. 3 ~ 8. 7%

Recovery

IV.

RESULTS

The effect of DDC on mean body weight in normal male albino rats is
illustrated in Fig. 4.

The mean body weight of the vehicle-treated animals

increased over a ten week period from an initial 180 g. to a final weight of
400 g. At the end of ten weeks of treatment the mean body weight of the
DDC-treated animals had increased to 350 g.

The drug-treated animals had a

significantly lower mean body weight than vehicle-treated animals after six
weeks of treatment with DDC.
Fig. 5 represents the effect of DDC treatment on body weight in unilaterally nephrectomized male albino rats.

The mean body weight of vehicle-treated

animals increased from 240 g. to 350 g. during the nine week study.

The mean

body weight of the DDC-treated animals increased from 230 to 300 g. during the
same period. There was a significant difference in body weight observed after
four weeks of treatment when DDC-treated animals were compared to controls.
The mean body weight of vehicle-treated versus DDC-treated renal
hypertensive male albino rats appears in Fig. 6.

The mean body weight of
•
the control animals increased to 450 g., whereas, mean body weight of the
DDC-treated animals increased to 375 g. after ten weeks of treatment. The
difference from control values became significant after two weeks of treatment

with DDC.
The method used to initiate renal hypertension proved successful. After
nine weeks of treatment the mean systolic blood pressure of the vehicle-treated
animals increased to 165 mm Hg (Fig. 9). The mean pressure of the surgically
intact and unilaterally nephrectomized groups of vehicle-treated animals remained relatively constant throughout the same period (Fig. 7 ,-8).
The effect of DDC treatment on systolic blood pressure in normal male
albino rats appears in Fig. 7. On the seventh week of treatment with DDC the
drug-treated animals had a significantly lower mean systolic blood pressure
when compared to vehicle-treated controls. At the end of eight weeks of treatment the pressure of the veh.icl0 - tre ated animals had

in c r eas~cl

from 115 to 125

mm Hg where a s that of the DDC - tr eatcd animals de ere ascd fro n1 115 to :
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1 ••

m m Hg.
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FIG. 4

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE
ON BODY WEIGHT IN MALE ALBINO RA TS.
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FIG.

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
BODY WEIGHT IN UNILATERAL J:-..TEPHRECTOMIZED MALE
ALBINO ~ATS.
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FIG.

6

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
BODY WEIGHT IN RENAL HYPERTENSIVE MALE ALBINO
RATS.
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FIG.

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
SYSTOLIC BLOOD PRESSURE IN MALE ALBINO RA TS.
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FIG.

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
SYSTOLIC BLOOD PRESSURE IN UNILATERAL NEPHRECTOMIZED MALE ALBINO RA TS.
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The systolic blood pressure of the unilaterally nephrectomized vehicletreated male albino rats increased from a mean of 100 mm Hg after seven weeks
of treatment (Fig. 8). A decrease in systolic blood pressure was observed in
the drug-treated unilaterally nephrectomized animals ranging from an initial
mean value of 110 mm Hg to a mean of 98 mm Hg after seven weeks of treatment with DDC.

The decrease in systolic blood pressure became significant

after the fourth week of treatment.
The hypotensive effect of DDC was more dramatic in renal hypertensive
animals (Fig. 9).

The mean systolic blood pressure of the vehicle-treated

renal hypertensive male albino rats increased from an initial value of 135 mm Hg
to a final value of 165 mm Hg.

However, the mean systolic blood pressure of

the DDC-treated animals decreased from a mean of 140 mm Hg initially to 100 mm
Hg after nine weeks of treatment. A significant difference from controls was
observed after four weeks of treatment with DDC in the renal hypertensive animals.
The effect of DDC treatment on urinary dopamine levels in normal male
albino rats is represented in Fig. 10.

There was no significant difference

observed between control and DDC-treated animals at any time during treatment.
Urinary dopamine levels of the vehicle-treated animals ranged from an initial
value of 22 µg/24 hr to a value of 20 µg/24 hr after nine weeks of treatment.
Similarly, urine dopamine levels of the DDC-treated animals ranged from a low
of 20 µg/24 hr _after two weeks of treatment to a high of 28 µg/24 hr after six weeks
of treatment, returning to normal after nine weeks of treatment.
Fig. 11 represents the effect of DDC on urinary dopamine in unilaterally
nephrectomized male albino rats. Urinary dopamine levels of the DDC-treated
animals increased from 18 µg/24 hr to 22 µg/24 hr after seven weeks of treatment. The mean urine dopamine levels of the controls decreased from a normal
of 15 µg/24 hr to 13 µg/24 hr after the same length of treatment.

There was a

significant difference between drug-treated and control animals observed after
seven weeks treatment with DDC.
The effect of DDC on urinary dopamine levels in renal hypertensive male
albino r a ts appears in Fig. 12. Mean urine dot1;_m1u1e level s of the cont r ols
increaser! fr o rn 15 µg / 2 4 hr to

'l ' 1i.., f1

of 18 ~1g /:24, hr af tec n ·~ le weeks of treat-
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THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
SYSTOLIC BLOOD PRESSURE IN RENAL HYPERTENSIVE
MALE ALBINO RA TS.
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FIG.
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THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
URINARY DOPAMINE (µg/24 hr) IN RENAL HYPERTENSNE
MALE ALBINO RATS • .
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FIG. 11

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMA TE ON
URINARY DOPAMINE (µg/24 hr) IN UNILATERAL NEPHRECTOMIZED MALE ALBINO RA TS.
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FIG. 12

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
URINARY DOPAMINE (µg/24 hr) IN MALE ALBINO RATS.

30

.,,_

....

.c

v
(\)

20

'.........

t:n

.~

w

z
-:iE
<(

a..

10

0
0

0 Vehicle

6. Na Diethyldithiocarbamate
0
0

2

4

. 6

8

10

WEEK OF TREATMENT
No significant difference (P < 0. 05) observe d b et\veen vehicle- and drugtreated groups. Drug dose s, (i. p .) on :-il tern ~~ te ·.Ll ;·s : Sodium diethyldi thioc:irbamate (66. 5 mg/kg), vc· :. fr i 2 , . 1'.l phos ph :t e 1-c1F {:1; , \H 7 . 4, (1 nu / k :n . :· · ··:h
point represents the me :iri -~ s . e . of six d(• L<:::rrnL u .., in ,l .~ • .

32

ment, whereas the total urinary dopamine of the DDC-treated animals ranged
from 20 µg/24 hr to a low of 17 µg/24 hr after nine weeks of treatment with
DDC. There was no significant difference from controls observed at any time
during treatment.
Urinary dopamine levels expressed as micrograms per kilogram of body
weight per 24 hours in normal animals are represented in Fig. 13. Dopamine
levels (µg/kg/24 hr) varied widely in the DDC and vehicle-treated normal
animals.

There was a tendency of the dopamine concentration of all animals to

decrease with decreasing weight, however, this trend proved to be statistically
insignificant.
Urine dopamine levels (µg/kg/24 hr) in the unilaterally nephrectomized
group of animals decreased from 33 to 22 µg/kg/24 hr in the vehicle-treated
group. After seven weeks of treatment with DDC, the urine dopamine levels
of the drug-treated group of animals decreased from 38 to 34 µg/kg/24 hr
becoming statistically significant from controls after the seventh week.
The urinary excretion of dopamine per kg per 24 hr did not differ significantly when renal hypertensive drug-treated animals were compared with vehicletreated renal hypertensive animals.

The dopamine levels of the latter group in-

creased from 21 µg/kg/24 hr to 24 µg/kg/24 hr whereas the urinary dopamine
excretion of the DDC-treated group decreased from 26 µg/kg/24 hr to 23 µg/
kg/24 hr. (Fig. 15)
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FIG.

13

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
URINARY DOPAMlliE IN MALE ALBINO RATS. (µg/kg/24 hr)
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FIG. 14

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
URINARY DOPAMINE IN UNILATERAL NEPHRECTOMIZED
MALE ALBINO RA TS. (µg/kg/24 hr)
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FIG. 15

THE EFFECT OF SODIUM DIETHYLDITHIOCARBAMATE ON
URINARY DOPAMINE IN RENAL HYPERTENSIVE MALE
ALBINO RATS. (µg/kg/24 hr)
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V. DISCUSSION
The time interval subsequent to initiation of treatment at which the body
weight of the DDC-treated animals became significantly different from that of
the controls appeared to reflect the am0tmt of functional kidney tissue in the
three groups of animals studied. This correlation was based on the assumption that a smaller number of nephrons were functional in r enal hypertensive
and unilaterally nephrectomized than in the normal animals.

The unilaterally

nephrectomized and renal hypertensive DDC-treated animals showed a significantly lower body weight than that of the control animals afte:r four and two
weeks of treatment, respectively.

The normal or surgically intact animals

showed this difference after six weeks of treatment with DDC.

This effect

may be due to a deficiency in detoxication or excretion as a result of decreased
functional kidney tissue thereby causing a cumulative effect.
The significant hypotensive effect observed in the three groups treated
with DDC agrees with the observations of Wohl et al. (1965). These authors
using desoxycorticosterone acetate-hypertensive rats noted a marked and
sustained hypotensive effect when 100 mg/kg of disulfiram was administered
intraperitoneally. An explanation of the hypo tensive effect on the basis of
increased circulating or tissue dopamine levels appears incongruous to the
findings of Pogrund et al. (1961), who demonstrated a pressor response to
dopamine in the rat. However,

Thoenen~

al. (1967) observed that after

inhibition of dopamine-/j-hydroxylase by disulfiram, dopamine incompletely
replaced the missing norepinephrine suggesting the affinity of dopamine for
storage sites is weaker than that · of norepinephrine.

This view appears to be

in agreement with the observations of Burn and Rand (1958). These authors
in an effort to explain the depressor effect of dopamine in guinea pig hypothesized that dopamine, when present in larger quantities than norepinephrine, occupied some of the vacated norepinephrine receptor sites. But, being a much
feebler constrictor agent, dopamine's occupation of the sites results in a loss of
vascular tone.

This supports the belief that the hypotensive effect observed in
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the DDC-treated animals in this study may be a consequence of decreased
norepinephrine levels.
An inability to demonstrate increased urinary dopamine levels with the
DDC-treated animals appears contradictory to the explanation of the hypotensive effect. However, dopamine has been reported to be the natural
substrate for MAO (Blaschko, 19 52). Since norepinephrine levels are depressed in DDC-treated animals, excess MAO would be available to metabolize
circulating or tissue dopamine. Although dopamine and norepinephrine concentrations were not measured in the kidney tissues, it would appear that the
dose of DDC administered was not sufficient to cause a large enough increase
in circulating dopamine to overcome the available MAO. As a result a significant increase in urinary dopamine could not be detected.
DeFanti and DeFeo (1963) reported finding a positive correlation between
increased excretion of dopamine (µg/kg/24 hr) and body weight (g.) for renal
hypertensive rats. However, a decrease in dopamine excretion was observed in
normotensive rats.
The decreased urinary dopamine (µg/kg/24 hr) observed in normotensive
rats in the present study agrees with the findings of DeFanti and DeFeo (1963)
and Leduc (1961). In normotensive DDC-treated animals however, there was a
tendency of the dopamine levels (µg/kg/24 hr) to increase to a greater degree

than that of the vehicle-treated animals , thus providing some indication that the
dopamine levels were increased as a result of the DDC treatment.

The slight

increase noted in the urinary dopamine levels (µg/kg/24 hr) of the vehicletreated group of renal hypertensive animals is in agreement with the previously
mentioned findings of De Fanti.

However, this slight increasing trend is not

enough evidence to warrant implication of dopamine in arterial hypertension.
Coates (1968) also reported finding no correlation between dopamine levels
and arterial blood pressure. A possible explanation for the

~iscrepancy

between

the findings in the present study and the observations of DeFanti may be found
in the assay methods used in the two studies.

As mentioned previously , alumina

was used in the present study for the extraction of dopamine from ur ine , where-
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as DeFanti used Dowex Sodium 50W-X8.

Coates (1968) reported finding that

Dowex resin was extracting a substance with native fluorescence from the urine
of rats and that the blank (Carlsson and Waldeck, 1958) by quenching this
fluorescence was resulting in erroneously high urinary dopamine levels.
Subsequently, by using alumina and altering the blank, this difficulty was
circumvented in the present study and allowed a more valid evaluation of
dopamine excretion in the renal hypertensive animals.
An apparent discrepancy to this explanation was the significant increase
in urinary dopamine observed in the unilaterally nephrectomized DDC-treated

group after seven weeks of treatment. An increase in urine volume per 24 hr
in the drug-treated group might explain the increased excretion of total dopamine,

however no significant difference was observed in the volume of urine excreted
from either group.

The large increase in dopamine excreted in the .D DC-treated

group may be explained on tre basis of an inhibition of dopamine-{3-hydroxylase,
however no such increase was observed in the DDC-treated renal hypertensive
group of rats, nor in the normal animals.

Further investigation into the mean-

ing of and explanation for the increased excretion of dopamine in DDC-treated
unilaterally nephrectomized rats appears necessary.

VI. SUMMARY AND CONCLUSIONS
Normal, unilaterally nephrectomized, and renal hypertensive male albino
rats were treated with diethyldithiocarbamate, a dopamine-(3-hydroxylase
inhibitor. Weight gain, systolic blood pressure, and urinary dopamine levels
were measured in an effort to further investigate the role of dopamine in
experimental hypertension. A significant hypotensive effect was observed in
the three groups treated with diethyldithiocarbamate when compared to vehicletreated control animals. Mean body weights of the drug-treated rats were
significantly lower than controls after six, four, and two weeks of treatment
in the normal, unilaterally nephrectomized, and renal hypertensive groups

respectively.

There appeared to be a positive correlation between decreasing

body weight, decreased amount of functional kidney tissue, and decreased
arterial blood pressure. There was no significant difference in urinary dopamine observed between drug-treated and control animals in either the normal
or renal hypertensive groups. After seven weeks of treatment with diethyldithiocarbamate, a significant increase iri urinary dopamine was observed in
the unilaterally nephrectomized drug-treated group when compared to controls.
No further explanation was offered, however, the results of this . study do not
indicate any correlation between arterial blood pressure and urinary dopamine
levels.
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